Cure8 news brief
This large real-world study suggests GLP-1 receptor agonists used in adults with Crohn’s disease and obesity were associated with lower healthcare use and lower subsequent TNF inhibitor use at 1 and 5 years, findings that could affect decisions about metabolic therapy in people with IBD but which are not definitive.
Adults with Crohn’s disease and obesity, clinicians managing IBD and metabolic comorbidities, and researchers studying GLP-1RAs or IBD outcomes.
This observational, propensity score–matched cohort study used the TriNetX electronic health record network to compare adults with Crohn’s disease and obesity who started GLP-1 receptor agonists (GLP-1RAs) versus matched nonusers.
Over 1- and 5-year fixed horizons the authors report lower mortality, fewer hospitalizations and ED visits, and lower subsequent TNF inhibitor use among GLP-1RA initiators; corticosteroid use was similar at 1 year and modestly lower at 5 years.
The study is retrospective and relies on EHR data with limited information about individual drug exposure (adherence, discontinuation, or switching). The authors note possible healthy-user bias and caution that the mortality difference should be considered hypothesis-generating rather than proof of a causal benefit.
The lower TNF inhibitor rate should not be interpreted as definitive evidence of less treatment escalation because initiation versus continuation could not be distinguished.
If you or your clinician are considering a GLP-1RA for weight or metabolic reasons, this study provides reassuring real-world safety signals in people with Crohn’s disease and obesity and suggests possible associations with lower healthcare use that deserve prospective study. It does not replace clinical judgment or randomized trial evidence.
Study details such as which specific GLP-1 agents were used, duration and adherence, and reasons for TNF inhibitor prescriptions are not fully captured in the database; prospective studies are needed to confirm these associations.
Retrospective EHR analyses can show associations but cannot prove cause-and-effect. Important exposure details (adherence, switching) were unavailable and healthy-user bias may influence results; the authors recommend prospective evaluation.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study suggests that regional differences in how often and how early advanced drugs are used didn’t change 10-year rates of surgery, hospitalization, or progression to complicated Crohn’s disease in this cohort.
Longer-term data help patients and clinicians understand whether an initial response to a new biologic (mirikizumab) is likely to last and whether safety findings remain acceptable over two years.
Early “top-down” infliximab plus an immunomodulator was linked to much lower 5-year risk of abdominal surgery, disease progression, and hospitalization versus a step-up approach. This could influence treatment planning...
